No Data
Yifan Pharmaceutical (002019.SZ): Ginkgo leaf pill does not involve national talks.
According to Yifan Pharmaceutical (002019.SZ) on November 12th, the company stated on the investor interaction platform that the products involved in this national negotiation are Dipyridamole Oral Suspension, and Ginkgo Biloba Capsules are not part of the negotiation.
yifan pharmaceutical (002019.SZ): Currently not shipping to the usa market.
GeLonghui November 7th | yifan pharmaceutical (002019.SZ) stated on the investor interaction platform that no shipments are currently being made to the usa market.
yifan pharmaceutical (002019): significant increase in sales of own products, remarkable results in improving quality and efficiency.
On October 31, 2024, the company released the third quarterly report of 2024. The total operating income for the first three quarters of 2024 reached 3.858 billion yuan, a year-on-year increase of 31.67%; net income attributable to the parent company was 0.366 billion yuan, a year-on-year increase of 14.
Yifan Pharmaceutical (002019): Performance maintains a high-speed growth trend. Yilishu's delivery in Europe has made breakthroughs in global expansion again.
The company released its Q3 report for 2024. In the first three quarters of 2024, total operating income was 3.858 billion yuan, a year-on-year increase of 31.67%; net income attributable to the parent company was 0.366 billion yuan, a year-on-year increase of 149.5%, net income attributable to the parent company after non-recurring items.
yifan pharmaceutical (002019): yilishu overseas shipments Joint venture company announces TCE human data in SLE, worth looking forward to.
In the first three quarters of 2024, the company achieved revenue of 3.858 billion yuan, a year-on-year increase of 31.7%; net income attributable to the parent company was 0.366 billion yuan, a year-on-year increase of 150%; net income excluding non-recurring items was 0.252 billion yuan, a year-on-year increase of 122.
Yifan Pharmaceutical: Report for the third quarter of 2024
No Data
No Data